Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

268
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
268
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

435
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
435
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

157
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
157
Factors Influencing Drug Absorption: Drug Dissolution01:27

Factors Influencing Drug Absorption: Drug Dissolution

1.2K
The pharmacokinetic journey of drugs from solid oral dosage forms into systemic circulation is multifaceted. It begins with disintegration, a prerequisite ensuring a solid dosage form's subdivision into minute particles. Dissolution occurs next as these granulated entities solubilize in gastrointestinal fluids. This solubilization is crucial for the succeeding stage, permeation, which describes the traversal of the drug across the intestinal membrane and its subsequent entry into the blood...
1.2K
Factors Affecting Protein-Drug Binding: Drug-Related Factors01:18

Factors Affecting Protein-Drug Binding: Drug-Related Factors

479
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
479
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

243
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of...
243

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NfL makes regulatory debut as neurodegenerative disease biomarker.

Nature reviews. Drug discovery·2023
Same author

NCATS's plan to grow the rare disease pipeline.

Nature reviews. Drug discovery·2023
Same author

GSK buys purine receptor antagonist for $2 billion.

Nature reviews. Drug discovery·2023
Same author

FDA approves second microbiome-based C. difficile therapy.

Nature reviews. Drug discovery·2023
Same author

Astellas buys complement inhibitor for $5.9 billion.

Nature reviews. Drug discovery·2023
Same author

Setting GPCRs free.

Nature reviews. Drug discovery·2023

Related Experiment Video

Updated: Jan 29, 2026

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
10:29

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Published on: November 12, 2010

40.5K

2018 FDA drug approvals

Asher Mullard

    Nature Reviews. Drug Discovery
    |February 3, 2019
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
    05:05

    Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

    Published on: November 4, 2011

    21.6K
    Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
    10:03

    Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

    Published on: August 1, 2013

    17.6K

    Related Experiment Videos

    Last Updated: Jan 29, 2026

    The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression
    10:29

    The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

    Published on: November 12, 2010

    40.5K
    Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
    05:05

    Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle

    Published on: November 4, 2011

    21.6K
    Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells
    10:03

    Generation of Recombinant Arenavirus for Vaccine Development in FDA-Approved Vero Cells

    Published on: August 1, 2013

    17.6K